2002 – CREATION OF LABORATOIRES DELBERT by Michel BERTHIER, pharmacist.
Experts in regulatory affairs, Michel Berthier and his daughter Laurence Delemotte, created Laboratoires DELBERT. The two pharmacists offer a service of regulatory activities: more than 300 Marketing Authorization files for generic drugs were registered in 10 years
2012 – LABORATOIRES DELBERT, A PHARMACEUTICAL COMPANY
Laboratoires DELBERT acquire their first pharmaceutical specialty: Bi-citrol® and become a pharmaceutical company with an “exploitant” status.
2013 – BIRTH OF A START UP
Laboratoires DELBERT are bought by Thierry HOFFMANN, industrial pharmacist and Marc CHILDS, psychiatrist.
2014 – CREATING A MODEL
Acquisition and return to the market of Vercyte® (Pipobroman).
In a context of shortage of Vercyte® specialty (Pipobroman), Laboratoires DELBERT acquired the product. They register a new supplier of active ingredients and find a production site for the finished product capable of handling highly toxic substances.
2016 – EXPANSION OF PRODUCT’S PORTFOLIO
Acquisition of the Piportil ® / Piportil ® L4 (Pipotiazine) range
Threatened with marketing discontinuation, Laboratoires DELBERT commit to maintaining PIPORTIL and PIPORTIL L4 in the psychiatric therapeutic arsenal.
2017 – REDEVELOP EUROPEAN KNOW-HOW
Returned to the market of Extencilline® (Benzathine benzylpénicilline)
Laboratoires DELBERT identify a European production site with an infrastructure suitable for the fermentation of penicillin. Reactivation of the production site allows benzathine benzylpenicillin-based medicine to be made available on the market again.
2018 – BEGINNING OF INTERNATIONALIZATION
Acquisition of the MAs for Bristopen® / Penstapho® / Prostaphlin® (Oxacillin) in France, Italy and the Czech Republic.
Acquisition of Mucomystendo® (Acétylcysteine) MAs in France
2019 – INTERNATIONALIZATION DEVELOPMENT
Launch of Oxycodone DELBERT®
Acquisition of the Marketing Authorization for Amukin® (Amikacine) and PENADUR® (benzathine benzyl penicillin) in Belgium and Luxembourg